 |
인쇄하기
취소
|
BMS’s Baraclude increase market share
The US based Bristol Myers Squibb’s Baraclude (entecavir) for treatment of hepatitis B accounted for about 50 percent of the sector’s domestic sales last year, an industry report showed yesterday.
Just within to two years of launch, Baraclude recorded 10 billion won in January, up 74.9 percent compared with the same period of last year.
Baraclude’s sales last year totaled 90 billion won, ...
Just within to two years of launch, Baraclude recorded 10 billion won in January, up 74.9 percent compared with the same period of last year.
Baraclude’s sales last year totaled 90 billion won, ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.